Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Jules Bordet Institute
Updated on 27 September 2022
measurable disease
bone marrow procedure
bortezomib
carfilzomib
daratumumab
refractory multiple myeloma

Summary

This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.

Details
Condition Lymphoproliferative Disorder, Multiple Myeloma, multiple myeloma (mm), Lymphoproliferative disorders
Treatment Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT
Clinical Study IdentifierNCT04379817
SponsorJules Bordet Institute
Last Modified on27 September 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note